167 related articles for article (PubMed ID: 36100309)
1. Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64).
Vavolizza RD; Petroni GR; Mauldin IS; Chianese-Bullock KA; Olson WC; Smith KT; Dengel LT; Haden K; Grosh WW; Kaur V; Varhegyi N; Gaughan EM; Slingluff CL
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36100309
[TBL] [Abstract][Full Text] [Related]
2. Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63).
Slingluff CL; Petroni GR; Chianese-Bullock KA; Wages NA; Olson WC; Smith KT; Haden K; Dengel LT; Dickinson A; Reed C; Gaughan EM; Grosh WW; Kaur V; Varhegyi N; Smolkin M; Galeassi NV; Deacon D; Hall EH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479025
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma.
Slingluff CL; Zarour HM; Tawbi HA; Kirkwood JM; Postow MA; Friedlander P; Devoe CE; Gaughan EM; Mauldin IS; Olson WC; Smith KT; Macri MJ; Ricciardi T; Ryan A; Venhaus R; Wolchok JD
Oncoimmunology; 2021 Mar; 10(1):1898105. PubMed ID: 33796406
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma.
Patel SP; Petroni GR; Roszik J; Olson WC; Wages NA; Chianese-Bullock KA; Smolkin M; Varhegyi N; Gaughan E; Smith KT; Haden K; Hall EH; Gnjatic S; Hwu P; Slingluff CL
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34413169
[TBL] [Abstract][Full Text] [Related]
5. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.
Slingluff CL; Petroni GR; Chianese-Bullock KA; Smolkin ME; Ross MI; Haas NB; von Mehren M; Grosh WW
J Clin Oncol; 2011 Jul; 29(21):2924-32. PubMed ID: 21690475
[TBL] [Abstract][Full Text] [Related]
6. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.
Melssen MM; Petroni GR; Chianese-Bullock KA; Wages NA; Grosh WW; Varhegyi N; Smolkin ME; Smith KT; Galeassi NV; Deacon DH; Gaughan EM; Slingluff CL
J Immunother Cancer; 2019 Jun; 7(1):163. PubMed ID: 31248461
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
Meneveau MO; Petroni GR; Salerno EP; Lynch KT; Smolkin M; Woodson E; Chianese-Bullock KA; Olson WC; Deacon D; Patterson JW; Grosh WW; Slingluff CL
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035112
[TBL] [Abstract][Full Text] [Related]
8. Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine.
Hu Y; Petroni GR; Olson WC; Czarkowski A; Smolkin ME; Grosh WW; Chianese-Bullock KA; Slingluff CL
Cancer Immunol Immunother; 2014 Aug; 63(8):779-86. PubMed ID: 24756419
[TBL] [Abstract][Full Text] [Related]
9. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.
Slingluff CL; Petroni GR; Olson WC; Smolkin ME; Ross MI; Haas NB; Grosh WW; Boisvert ME; Kirkwood JM; Chianese-Bullock KA
Clin Cancer Res; 2009 Nov; 15(22):7036-44. PubMed ID: 19903780
[TBL] [Abstract][Full Text] [Related]
10. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
11. Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial.
Ninmer EK; Zhu H; Chianese-Bullock KA; von Mehren M; Haas NB; Ross MI; Dengel LT; Slingluff CL
Nat Commun; 2024 Mar; 15(1):2570. PubMed ID: 38519525
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma.
Mørk SK; Skadborg SK; Albieri B; Draghi A; Bol K; Kadivar M; Westergaard MCW; Stoltenborg Granhøj J; Borch A; Petersen NV; Thuesen N; Rasmussen IS; Andreasen LV; Dohn RB; Yde CW; Noergaard N; Lorentzen T; Soerensen AB; Kleine-Kohlbrecher D; Jespersen A; Christensen D; Kringelum J; Donia M; Hadrup SR; Marie Svane I
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782542
[TBL] [Abstract][Full Text] [Related]
13. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.
Fourcade J; Sun Z; Pagliano O; Chauvin JM; Sander C; Janjic B; Tarhini AA; Tawbi HA; Kirkwood JM; Moschos S; Wang H; Guillaume P; Luescher IF; Krieg A; Anderson AC; Kuchroo VK; Zarour HM
Cancer Res; 2014 Feb; 74(4):1045-55. PubMed ID: 24343228
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival.
Reed CM; Cresce ND; Mauldin IS; Slingluff CL; Olson WC
Clin Cancer Res; 2015 Sep; 21(17):3879-87. PubMed ID: 25967144
[TBL] [Abstract][Full Text] [Related]
15. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602).
Slingluff CL; Lee S; Zhao F; Chianese-Bullock KA; Olson WC; Butterfield LH; Whiteside TL; Leming PD; Kirkwood JM
Clin Cancer Res; 2013 Aug; 19(15):4228-38. PubMed ID: 23653149
[TBL] [Abstract][Full Text] [Related]
16. Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors.
Rahma OE; Tyan K; Giobbie-Hurder A; Brohl AS; Bedard PL; Renouf DJ; Sharon E; Streicher H; Hathaway E; Cunningham R; Manos M; Severgnini M; Rodig S; Stephen Hodi F
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264434
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines.
Slingluff CL; Petroni GR; Smolkin ME; Chianese-Bullock KA; Smith K; Murphy C; Galeassi N; Neese PY; Grosh WW; Nail CJ; Ross M; von Mehren M; Haas N; Boisvert ME; Kirkwood JM
J Immunother; 2010; 33(6):630-8. PubMed ID: 20551833
[TBL] [Abstract][Full Text] [Related]
18. Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.
Tang B; Yan X; Sheng X; Si L; Cui C; Kong Y; Mao L; Lian B; Bai X; Wang X; Li S; Zhou L; Yu J; Dai J; Wang K; Hu J; Dong L; Song H; Wu H; Feng H; Yao S; Chi Z; Guo J
J Hematol Oncol; 2019 Jan; 12(1):7. PubMed ID: 30642373
[TBL] [Abstract][Full Text] [Related]
19. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
20. Peptide emulsions in incomplete Freund's adjuvant create effective nurseries promoting egress of systemic CD4
Melssen MM; Fisher CT; Slingluff CL; Melief CJM
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36939214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
